[1]
|
J. Ferlay, F. Bray, Pisani, et al., “GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5. Version 2.0,” IARC Press, Lyon, 2004.
|
[2]
|
A. Jemal, R. Siegel and E. Ward, “Cancer Statistics,” CA: A Cancer Journal for Clinicians, Vol. 57, No. 1, 2007, pp. 43-66.
|
[3]
|
J. P. Pignon, J. Bourhis, C. Domenge and L. Designe, “Chemotherapy Added to Loco-Regional Treatment for Head and Neck Squamous Cell Carcinoma: Three Meta-Analyses of Updated Individual Data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer,” Lancet, Vol. 355, 2000, pp. 949-955. doi:10.1016/S0140-6736(00)90011-0
|
[4]
|
J. P. Pignon, A. Le Maitre, E. Maillard and J. Bourhis, “Meta-Analysis of Chemotherapy in Head and Neck Cancer (MACH-NC): An Update on 93 Randomised Trials and 17,346 Patients,” Radiotherapy & Oncology, Vol. 92, 2009, pp. 4-14. doi:10.1016/j.radonc.2009.04.014
|
[5]
|
D. J. Adelstein, Y. Li, G. L. Adams, et al., “An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients with Unresectable Squamous Cell Head and Neck Cancer,” Journal of Clinical Oncology, Vol. 21, No. 20, 2003, pp. 92-98.
|
[6]
|
A. S. Garden, J. Harris, E. E. Vokes, et al., “Preliminary results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck,” Journal of Clinical Oncology, Vol. 22, No. 14, 2004, pp. 2856-2864.
|
[7]
|
P. Sanghera, C. McConkey, K. F. Ho, et al., “Hypofractionated Accelerated Radiotherapy with Concurrent Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck,” International Journal of Radiation Oncology*Biology*Physics, Vol. 67, No. 1, 2007, pp. 342-1351.
|
[8]
|
A. Trotti and S. M. Bentzen, “The Need for Adverse Effects Reporting Standards in Oncology Clinical Trials,” Journal of Clinical Oncology, Vol. 22, No. 1, 2004, pp. 19-22.
|
[9]
|
J. A. Bonner, P. M. Harari, J. Giralt, et al., “Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck,” New England Journal of Medicine, Vol. 354, No. 6, 2006, pp. 567-578.
|
[10]
|
M. Peyrone, “Ueber Die Einwirkung des Ammoniaks auf Platinchlorür,” Ann Chemie Pharm, Vol. 51, No. 1, 1844, pp. 1-29. doi:10.1002/jlac.18440510102
|
[11]
|
S. Trzaska, “Cisplatin,” Chemical & Engineering News, Vol. 83, No. 25, 2005, pp. 1-162.
http://pubs.acs.org/cen/coverstory/83/8325/8325cisplatin.html.
|
[12]
|
B. Rosenberg, L. Van Camp and T. Krigas, “Inhibition of Cell Division in Escherichia coli by Electrolysis Products from a Platinum Electrode,” Nature, Vol. 205, No. 4972, 1965, pp. 698-699. doi:10.1038/205698a0
|
[13]
|
D. P. Carpenter, “Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA,” Princeton University Press, Princeton, 2010.
|
[14]
|
N. Sawada, T. Ishikawa, F. Sekiguchi, et al., “X-Ray Irradiation Induces Thymidine Phosphorylase and Enhances the Efficacy of Capecitabine (Xeloda) in Human Cancer Xenografts,” Clinical Cancer Research, Vol. 5, 1999, pp. 2948-2953.
|
[15]
|
A. J. Sykes, N. J. Slevin, R. H. MacDougall, et al., “Results of a Phase I Study to Determine the Maximum Tolerated Dose of Capecitabine When Given Concurrently with Radical Radiotherapy in the Treatment of Squamous Cell Carcinoma of the Head and Neck,” Radiotherapy & Oncology, Vol. 71, No. 1, 2004, pp. 81-84.
|
[16]
|
C. F Lacy, L. L. Armstrong, M. P. Goldman and L. L. Lance, “Lexi-Comp’s Drug Information Handbook,” 12th Edition, Lexi-Comp Inc., 2004.
|
[17]
|
J. S. Tobias, K. Monson, N. Gupta, et al., “Chemoradiotherapy for Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of the UK Head and Neck (UKHAN1) Trial,” Lancet Oncology, Vol. 11, No. 1, 2010, pp. 66-74.
|
[18]
|
O. Matzinger, A. Zouhair, R. O. Mirimanoff and M. Ozsahin, “Radiochemotherapy in Locally Advanced Squamous Cell Carcinomas of the Head and Neck,” Clinical Oncology (Royal College of Radiologists), Vol. 21, No. 7, 2009, pp. 525-531.
|
[19]
|
G. P. Browman, C. Cripps, D. I. Hodson, et al., “Placebo-Controlled Randomized Trial of Infusional Fluorouracil during Standard Radiotherapy in Locally Advanced Head and Neck Cancer,” Journal of Clinical Oncology, Vol. 12, No. 12, 1994, pp. 2648-2653.
|
[20]
|
M. A. Bagshaw, “Possible Role of Potentiators in Radiation Therapy,” American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine, Vol. 85, 1961, pp. 822-833.
|
[21]
|
L. Griffiths and I. J. Stratford, “The Influence of Elevated Levels of Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase on Tumourigenicity, Tumour Growth, and Oxygenation,” International Journal of Radiation Oncology*Biology*Physics, Vol. 42, 1998, pp. 877-883.
|
[22]
|
P. Huguenin, K. T. Beer, A. Allal, et al., “Concomitant Cisplatin Significantly Improves Locoregional Control in Advanced Head and Neck Cancers Treated with Hyperfractionated Radiotherapy,” Journal of Clinical Oncology, Vol. 22, No. 23, 2004, pp. 4665-4673.
|
[23]
|
E. E. Cohen, M. W. Lingen and E. E. Vokes, “The Expanding Role of Systemic Therapy in Head and Neck Cancer,” Journal of Clinical Oncology, Vol. 22, No. 9, 2004, pp. 1743-1752.
|
[24]
|
B. Jeremic, Y. Shibamoto, B. Stanisavljevic, et al., “Radiation Therapy Alone or with Concurrent Low-Dose Daily either Cisplatin or Carboplatin in Locally Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck: A Prospective Randomized Trial,” Radiotherapy & Oncology, Vol. 43, No. 1, 1997, pp. 29-37.
|
[25]
|
P. M. Specenier, W. D. van den, C. Van Laer, et al., “Phase II Feasibility Study of Concurrent Radiotherapy and Gemcitabine in Chemonaive Patients with Squamous Cell Carcinoma of the Head and Neck: Long-Term Follow Up Data,” Annals of Oncology, Vol. 18, 2007, pp. 1856-1860. doi:10.1093/annonc/mdm346
|